

Monthly DRUP Study Newsletter #82, 01 February 2023

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

Study update

To date, a total of 2493 cases have been submitted to the study team and 1320 of these have started a treatment within DRUP.

The DRUP drug arsenal currently includes more than 30 different drugs. For a complete overview please visit our website at www.drupstudy.nl and log in to the protected area (login details can be requested via drup@nki.nl). Together with a list of all available study drugs, you can also find an up-to-date overview of all open cohorts. Important to mention here is that new cohorts are being opened continuously, so do not hesitate to contact the DRUP study team if you have an eligible patient for any of the available drugs, but cannot find a suitable cohort on the website.

Scientific output

We're excited to share with you that the paper titled "γδ T cells are effectors of immunotherapy in cancers with HLA class I defects" has been published in Nature! The paper describes the findings of how B2M (b2-microglobulin) mutant MMR-d/MSI-H cancers in the DRUP study showed significantly enhanced responsiveness to immune checkpoint inhibition (ICI) and also consistently showed increased infiltration by γδ T cells. With further in vitro experiments and by comparing tumor samples obtained before and after ICI, it was found that ICI profoundly increased the intratumoral frequency of γδ T cells in HLA class I-negative cancers, indicating that γδ T cells are effectors of ICI therapy in patients with HLA class I-negative, MMR-d/MSI-H colon cancers. This research would not have been possible without the efforts and cooperation of all people involved in the DRUP trial and we thank everyone who contributed. The paper can be found via the following link: <https://www.nature.com/articles/s41586-022-05593-1>

Study team update

After four years of working for DRUP and DRUG Access, our trial manager Lena Bilet has decided to leave the study team to take on a new challenge in her career. Thanks to her influence and her important role in process efficiency in many aspects, the studies have been highly professionalized. We are therefore very sorry to see her leave the team, are grateful for her contribution to the studies and wish her all the best on her future endeavors. Lena's last day of work is Friday February 10th.

Report first European meeting

As some of you know, trials similar to DRUP have been implemented in several European countries. DRUP-like studies are already running in 6 European countries: The Netherlands, the UK, Norway, Denmark, Sweden and Finland. Another 10 countries are planning to implement DRUP-like studies.

To kick-start the collaboration between the different DRUP-like trials, the PCM4EU kick-off meeting took place at the Leiden University Medical Center on the 18th and 19th of January! More than 40 participants from 14 different European countries came to Leiden to stimulate closer collaboration between DRUP like trials across Europe and to help set up new DRUP-like studies. During the 2 fruitful days many aspects of the collaboration were discussed, such as the implementation of DRUP-like trials across the EU and the data pooling of results, the molecular diagnostics used across the different trials, equitable access to molecular clinical trials and many more. As DRUP team we are very happy to see the international partnership grow and look forward to collaborate with our partners more closely!



A little teaser for upcoming month

The coming month we will give our newsletter a little makeover. Among other things, it will be a combined newsletter including both the DRUP study and the DRUG Access Protocol (DAP) and it will also get a brand new layout. Furthermore, four times a year, instead of our monthly newsletter, a special issue in collaboration with the Center for Personalized Cancer Treatment (CPCT) will be distributed to all DRUP, DAP and CPCT readers.

Best regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest

Study Coordinators: Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon

Clinical Project Manager: Lena Bilet

Table 1: List of pharmaceutical companies & study drugs

Confidential, list might be subjected to change

Currently available

<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>MSD</u> Pembrolizumab	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Lilly</u> Abemaciclib Selpercatinib	Vemurafenib+ Cobimetinib Vismodegib
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib	<u>Janssen</u> Erdafitinib	Atezolizumab+ bevacizumab Alectinib Entrectinib

Committed

<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib
-------------------------	---------------------------

Calendar & publicity

IDMC meeting 21st of March 2023

Table 2: Submission and accrual overview stage 1,2 & 3 cohorts

Feb 1st, 2023

